Developmental Therapeutics Branch

Chief
Yves Pommier, M.D., Ph.D.

The Developmental Therapeutics Branch advances novel therapeutic strategies and conducts clinical trials based on cancer-specific genomic, epigenetic and metabolic alterations, drug design, molecular mechanisms of drug action to achieve precision medicine. The branch integrates both basic and translational science programs. The basic program focuses on cancer-specific genomic and epigenomic alterations, oxidative signaling, molecular pharmacology and drug resistance. The translational clinical program focuses on novel therapeutic agents across a spectrum of diseases and disease mechanisms. Novel therapeutic modalities are selected based on pharmacodynamic and genomic biomarkers and mechanistic hypotheses to assess clinical activity and molecular determinants of response at the early phase of drug development.

The Developmental Therapeutics Branch is organized in several research groups lead by Principal Investigators focusing on complementary areas of interest. The research laboratories and the administrative staff are located in building 37, except for Dr. Jane B. Trepel, whose laboratory is located in building 10. The clinical trials are conducted at the Clinical Center in building 10.

The Developmental Therapeutics Branch includes a Genomics and Bioinformatics Group (managed by William C. Reinhold under the leadership of Dr. Yves Pommier). The Genomics and Bioinformatics Group explores the relationships between genomic alterations in malignant cells and their response to chemotherapeutic agents using molecular databases at the DNA, RNA and protein levels.


There are no Open Positions at this time. Check back again later, or take a look at CCR's Careers page.


Resources

Genomics and Bioinformatics Tools 

Drugs Against Cancer: https://discover.nci.nih.gov/kohn-book-drugs-against-cancer.jsp Stories of Discovery and the Quest for a Cure 

The Branch’s Genomics and Bioinformatics Group explores the relationships between genomic alterations in malignant cells and their response to chemotherapeutic agents using molecular databases at the DNA, RNA and protein levels.

The Miner Suite of bioinformatic software packages developed by the Group are freely available for public use. Visit the links below to learn more about each one.

The CellMiner Cross Database (CDB) enables exploration and analysis of cancer cell line pharmacogenomic data across different sources.

CellMiner is a database and query tool designed for the cancer research community to facilitate integration of the molecular datasets generated by the Facility/Group? and its collaborators on the NCI-60.

CIMminer produces Clustered Image Maps (CIMS) (i.e., clustered heat maps).

GoMiner leverages the Gene Ontology (GO) database for biological interpretation of microarray data.

High-Throughput GoMiner is a tool for batch processing of multiple microarrays and integrated CIMs of the GoMiner results.

MIMminer is a repository of electronically navigatable Kohn Molecular Interaction Maps (MIMs).

SpliceCenter is a suite of user-friendly tools designed for use by every bench biologist who needs to check for the impact of gene splice variation on common molecular biology technologies, including RT-PCR, RNAi, expression microarrays, and peptide-based assays.

AbMiner allows allows users to search for appropriate, commercially available antibodies for research purposes, and to match each antibody to its respective genomic identifiers.

Branch News:

Drugs Against Cancer: Stories of Discovery and the Quest for a Cure by Dr. Kurt Kohn

The Developmental Therapeutics Branch of the NCI is happy to announce the online publication of the first public version of a new book entitled "Drugs Against Cancer: Stories of Discovery and the Quest for a Cure" by Dr. Kurt Kohn, an NIH Scientist Emeritus. The aim of the book is to explain how the knowledge and application of cancer chemotherapy drugs developed. This book is an account of the earliest published work leading to the anti-cancer drug discovery and to explain how the knowledge and application of cancer chemotherapy drugs developed.

Dr. Kohn devoted nearly 60 years of his life to anti-cancer drug research at the National Cancer Institute. In the book, he wrote "I felt a responsibility to make a record of the part of the cancer drug development effort with which I was associated, going back nearly 60 years, and to relate it to the global anti-cancer drug discovery and development efforts." It is in large part a historical account, a combination of science, history, medicine, and memoir.

Chapters can be downloaded individually and new chapters are continuously added. Book chapters are available at: https://discover.nci.nih.gov/kohn-book-drugs-against-cancer.jsp

About

The Developmental Therapeutics Branch advances novel therapeutic strategies and conducts clinical trials based on cancer-specific genomic, epigenetic and metabolic alterations, drug design, molecular mechanisms of drug action to achieve precision medicine. The branch integrates both basic and translational science programs. The basic program focuses on cancer-specific genomic and epigenomic alterations, oxidative signaling, molecular pharmacology and drug resistance. The translational clinical program focuses on novel therapeutic agents across a spectrum of diseases and disease mechanisms. Novel therapeutic modalities are selected based on pharmacodynamic and genomic biomarkers and mechanistic hypotheses to assess clinical activity and molecular determinants of response at the early phase of drug development.

The Developmental Therapeutics Branch is organized in several research groups lead by Principal Investigators focusing on complementary areas of interest. The research laboratories and the administrative staff are located in building 37, except for Dr. Jane B. Trepel, whose laboratory is located in building 10. The clinical trials are conducted at the Clinical Center in building 10.

The Developmental Therapeutics Branch includes a Genomics and Bioinformatics Group (managed by William C. Reinhold under the leadership of Dr. Yves Pommier). The Genomics and Bioinformatics Group explores the relationships between genomic alterations in malignant cells and their response to chemotherapeutic agents using molecular databases at the DNA, RNA and protein levels.

Clinical Trials

PI & Key Staff

Positions


There are no Open Positions at this time. Check back again later, or take a look at CCR's Careers page.


Contact Info

Developmental Therapeutics Branch
Center for Cancer Research
National Cancer Institute
Building 37, Room 5068A
Bethesda, MD 20892-4264
Ph: 240-760-7317
Fax: 240-541-4475
Clinical Program Coordinator (Contr.)
240-760-7131